GleamWall
中文EN

DYN Dyne Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1818794 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.7%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-74.6%
ROA-57.6%
ROIC (approx.)-225.2%
Asset turnover—

Leverage & solvency

Liabilities / assets24.6%
Debt / equity0.21x
Current ratio12.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$398.33M$281.41M
SG&A expense$69.85M$62.48M
Operating income-$468.18M-$343.89M
Income tax$0$0
Net income-$446.21M-$317.42M
EBITDA-$466.13M-$342.21M
EPS (basic)-3.47-3.37
EPS (diluted)-3.47-3.37
Balance sheet
Cash & equivalents$893.37M$435.45M
Short-term investments$217.19M$206.82M
Current assets$1.13B$659.28M
PP&E, net$24.03M$5.40M
Total assets$1.19B$691.23M
Current liabilities$50.62M$42.26M
Long-term debt$148.92M$0
Total debt$148.92M$0
Total liabilities$214.83M$61.40M
Shareholders' equity$972.13M$629.84M
Net debt-$744.45M-$435.45M
Shares outstanding164.95M102.32M
Cash flow statement
Operating cash flow-$403.21M-$292.37M
Capital expenditure$1.92M$2.38M
Free cash flow-$405.13M-$294.75M
Investing cash flow-$28.75M-$204.08M
Financing cash flow$890.31M$809.89M
Depreciation & amortization$2.05M$1.67M
Stock-based compensation$45.85M$45.86M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.